Skip to main content

Table 2 Prognostic value of pathological tumour response for VEGFR-1, VEGFR-2, and TKTL1

From: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy

  VEGFR-1/GUS ≤
Median (n = 13)
VEGFR-1/GUS >
Median (n = 13)
p-value
TRG 2 - 3 9 (69.2%) 8 (61.5%) p = 1.0
pCR* (ypT0 N0) 2 (15.4%) 1 (7.7%) p = 1.0
  VEGFR-2/GUS ≤
Median (n = 16)
VEGFR-2/GUS >
Median (n = 16)
 
TRG 2 - 3 12 (75%) 9 (56%) p = 0.19
PCR* (ypT0 N0) 2 (16.7%) 1 (6.3%) p = 1.0
  TKTL1/GUS ≤
Median (n = 17)
TKTL1/GUS >
Median (n = 16)
 
TRG┼ 2 - 3 11 (64.5%) 11 (68.8%) p = 1.0
PCR* (ypT0 N0) 1 (5.9%) 2 (12.5%) p = 0.6
  1. pathological complete remission, Tumour regression grading